These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
    Author: Nakano M, Kusaba H, Makiyama A, Ariyama H, Arita S, Oda H, Esaki T, Takayoshi K, Uchino K, Tamura S, Kumagai H, Iwama E, Shirakawa T, Mitsugi K, Takaishi S, Akashi K, Baba E.
    Journal: Anticancer Res; 2014 Jan; 34(1):215-20. PubMed ID: 24403465.
    Abstract:
    BACKGROUND: Malignant peritoneal mesothelioma (PM) is an extremely rare disease. Pemetrexed and platinum have been used for advanced PM following malignant pleural mesothelioma (PLM). Because PM differs considerably from PLM in clinical features, the efficacy and safety of these therapies have yet to be established. PATIENTS AND METHODS: Six Japanese patients with PM who had been treated with pemetrexed-based chemotherapy in four Institutions were retrospectively identified. Treatment response, progression-free survival, and overall survival were examined. Toxicities of therapy were also evaluated. RESULTS: Three patients with mild ascites achieved clinical benefits (one with partial response and two with stable disease). Treatments with reduced cisplatin or carboplatin for patients with massive ascites were safely performed. Median PFS and OS were 7.2 and 13.1 months, respectively. Grade 3 hematological toxicities appeared in two patients with massive ascites. CONCLUSION: Selection of chemotherapy based on the patient's condition, such as ascites, might be important for advanced PM.
    [Abstract] [Full Text] [Related] [New Search]